TrialAnnals of the rheumatic diseases2020

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.

Désirée van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.